Oncology
China’s PD-1/VEGF Bet Challenges the Lung Cancer Backbone
HARMONi-6 showed an overall survival advantage for ivonescimab plus chemotherapy over PD-1 plus chemotherapy in first-line squamous NSCLC, putting China-origin oncology innovation directly into the global standard-of-care debate.
EU Cancer Policy Moves Back Into Budget Politics
Genomic Matching Works When the Evidence Is Strong Enough to Act
England’s Cancer Plan Turns Personalised Care Into a National Delivery Test
Cancer Drugs Put Europe’s New HTA System to Its First Real Test
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.